Femasys Inc.
$0.42
▲
5.32%
2026-04-21 06:49:01
www.femasys.com
NCM: FEMY
Explore Femasys Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$25.6 M
Current Price
$0.42
52W High / Low
$1.29 / $0.31
Stock P/E
—
Book Value
$0.1
Dividend Yield
—
ROCE
-460.52%
ROE
-4.56%
Face Value
—
EPS
$-0.47
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
51
Beta
-2.28
Debt / Equity
80.03
Current Ratio
4.53
Quick Ratio
2.95
Forward P/E
-1.12
Price / Sales
10.45
Enterprise Value
$19.41 M
EV / EBITDA
-1.12
EV / Revenue
8.46
Rating
Buy
Target Price
$3.67
EPS Forecast (FY)
—
Pros
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | NEXGEL, Inc. | $0.64 | — | $6.98 M | — | -41.75% | -52.74% | $2.99 / $0.56 | $0.64 |
| 2. | Becton, Dickinson and Company | $155.63 | 25.5 | $44.7 B | 2.65% | 6.35% | 6.96% | $187.35 / $127.54 | $88.79 |
| 3. | Anbio Biotechnology | $26.98 | 380.56 | $3.88 B | — | 11.61% | 27.05% | $55.65 / $6.05 | $0.63 |
| 4. | Pulse Biosciences, Inc. | $23.73 | — | $1.61 B | — | -88.83% | -74.45% | $26.3 / $12.56 | $1.19 |
| 5. | LeMaitre Vascular, Inc. | $115 | 44.97 | $2.6 B | 0.87% | 11.72% | 15.8% | $118.01 / $78.01 | $17.28 |
| 6. | Azenta, Inc. | $26.4 | — | $1.22 B | — | -1.19% | 1.53% | $41.73 / $19.87 | $37.26 |
| 7. | AptarGroup, Inc. | $125.33 | 21.29 | $8.05 B | 1.47% | 12.5% | 15.1% | $164.28 / $103.23 | $41.56 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.81 M | 0.73 M | 0.41 M | 0.34 M | 0.58 M | — |
| Operating Profit | -4.62 M | -3.65 M | -3.85 M | -5.46 M | -4.72 M | — |
| Net Profit | -3.95 M | -4.19 M | -4.59 M | -5.9 M | -5.12 M | — |
| EPS in Rs | -0.07 | -0.07 | -0.08 | -0.1 | -0.08 | -0.24 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.29 M | 1.63 M | 1.07 M | 1.21 M |
| Operating Profit | -17.59 M | -17.79 M | -14.51 M | -11.6 M |
| Net Profit | -18.63 M | -18.82 M | -14.25 M | -11.39 M |
| EPS in Rs | -0.31 | -0.31 | -0.24 | -0.19 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 20.72 M | 12.45 M | 27.76 M | 16.9 M |
| Total Liabilities | 14.85 M | 10.14 M | 9.4 M | 1.65 M |
| Equity | 5.87 M | 2.3 M | 18.35 M | 15.24 M |
| Current Assets | 16.46 M | 8.02 M | 23.18 M | 14.13 M |
| Current Liabilities | 3.64 M | 8.58 M | 3.05 M | 1.53 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -18.69 M | -19.44 M | -11.28 M | -10.73 M |
| Investing CF | -0.63 M | -0.85 M | -0.14 M | -0.41 M |
| Financing CF | 25.14 M | 2.03 M | 20.18 M | -0.68 M |
| Free CF | -19.32 M | -20.29 M | -11.42 M | -11.14 M |
| Capex | -0.63 M | -0.85 M | -0.14 M | -0.41 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 51.97% | -11.13% | — | — |
| Earnings Growth % | -32.07% | -25.04% | — | — |
| Profit Margin % | -1155.03% | -1329.06% | -944.62% | — |
| Operating Margin % | -1091.75% | -1353.43% | -961.71% | — |
| Gross Margin % | 66.55% | 64.54% | 63.36% | — |
| EBITDA Margin % | -1002.48% | -1228.52% | -869.27% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.